Home » Training & Examinations » Pharmaceutical Medicine Specialty Training » Enrolment and training » Training sites

Training sites

Training sites are organisations that have been approved by the GMC to deliver the pharmaceutical medicine specialty training programme. Training sites are responsible for supporting their trainees and specialty trainers and to fulfil the requirements in the GMC's 'Promoting excellence: standards for medical education and training'.

Training site approval

Pharmaceutical medicine organisations that would like to deliver the PMST programme, must be approved by the GMC.

We will submit a training approval application to the GMC if the pharmaceutical medicine organisation has:

completed the PMST training site self-assessment form (see ‘Resources’ section below) in full; and
answered ‘Yes’ to all of the statements under the four domains.

The four domains are:

Learning environment and culture
Educational governance and leadership
Supporting and empowering pharmaceutical medicine trainees
Supporting and empowering pharmaceutical medicine educational and associate educational supervisors.

If a pharmaceutical medicine organisation answers ‘No’ to any of the domain statements on their self-assessment form, we may ask one of our FPM Specialty Advisors (SAs) to meet the pharmaceutical medicine organisation and complete an assessment of the organisation’s suitability to become an approved training site before we consider submitting an application to the GMC.

After the GMC has approved a pharmaceutical medicine organisation as a training site, its name will be added to the GMC’s list of approved training locations.

The training site must then meet the standards and requirements of the GMC, which are contained in ‘Promoting excellence: standards for medical education and training’, on an ongoing basis. We may request the training site to submit an annual self-assessment form to us so that we can monitor its delivery of the PMST programme for its trainees and educational supervisors.

Forms and guidance

List of existing PMST training sites

We will keep the list up to date, but you are advised to verify that the pharmaceutical medicine organisation is still a GMC-approved training site and suitable to support pharmaceutical physicians who want to undertake PMST. The list is for information only.

Accellacare
Achilles Therapeutics
ADC Therapeutics (UK) Ltd
Allergy Therapeutics Ltd
Amgen Ltd
AstraZeneca UK Ltd

External Educational Supervisors

FPM maintains a list of external educational supervisors that pharmaceutical medicine organisations can request if they are unable to provide their trainees with in-house educational supervision.

Please contact FPM’s Specialty Training Manager for a copy. We recommend you read the conditions of using the list below first before you request a copy.

Conditions for using external educational supervisor list

2.1 Pharmaceutical organisations, potential and current doctors in training

The list must only be used to find an external educational supervisor to supervise doctors enrolled on the PMST programme.

The information contained in this list is confidential and should not be passed to other parties.

Pharmaceutical organisations must either complete an agreement or contract with an external educational supervisor to hire their services in good faith or notify the external educational supervisor that it does not want to proceed with an agreement or contract immediately, and before the external educational supervisor has incurred costs in preparation to sign the agreement or contract, otherwise the pharmaceutical organisation may be liable for all costs incurred by the external educational supervisorr.

2.2 External educational supervisors

The external educational supervisor has agreed to enter his or her name on to this list for acting as an external educational supervisor for doctors enrolled on the PMST programme only.

The external educational supervisor agrees to tell FPM if they:

want to be removed from the list; and/or
have relinquished your licence to practise with the GMC.

It is the responsibility of the pharmaceutical organisation to negotiate, set or agree fees directly with the external educational supervisor for the performance of this service.

FPM is not responsible for negotiating, setting or agreeing fees that may be payable to the external educational supervisor for the performance of this service.

On no account must the doctor in training be responsible for negotiating, setting or agreeing fees with the external educational supervisor either directly or indirectly (e.g. via the doctor in training’s limited company if s/he is working as an independent pharmaceutical physician) for the performance of this service.

On no account must the external educational supervisor receive payment from the doctor in training either directly or indirectly (e.g. via the doctor in training’s limited company if s/he is working as an independent pharmaceutical physician) for the performance of this service.

Agreements or contracts or both, regarding hours of work, confidentiality, termination of work in the performance of this service, are between the pharmaceutical organisation and the external educational supervisor only. The termination of the external educational supervisor’s work must not impact on the progress of a doctor in training through the PMST programme, and the pharmaceutical organisation must plan the continued educational supervision of the doctor in training as early as possible.

All individuals entered on the list have completed appropriate training to undertake the role of an external educational supervisor, and have agreed to meet the following conditions in the performance of this role:

undertake induction training before s/he is fully recognised as an educational supervisor and attend update sessions about every two years or as required;
be prepared to be an educational supervisor for a trainee, recognising the time commitment that this entails;
be willing to provide on-going supervision and monitoring of trainees’ performance in accordance with the GMC’s guidance on ‘Good Medical Practice’;
bewilling to attend each annual review; Annual Review of Competence Progression (ARCP);
be prepared to provide support, if required, for a reasonable period (e.g. 12 months) after the trainee has been awarded an ARCP outcome 6 to ensure that the trainee is entered on the GMC’s Specialist Register; and
fully engage in the revalidation process.

Back to PMST